SCHEMBL31104205

SCHEMBL31104205

C[Si](C)(C)CCOCn1ncc(CCC=O)c(Cl)c1=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.33
▸ HTT P42858 5/20 0.33
▸ RAB9A P51151 5/20 0.33
▸ NPSR1 Q6W5P4 5/20 0.33
▸ NPC1 O15118 3/20 0.33
▸ S1PR2 O95136 3/20 0.33
▸ LMNA P02545 3/20 0.33
▸ HCRTR1 O43613 1/20 0.33
▸ S1PR4 O95977 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ S1PR1 P21453 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ TLR9 Q9NR96 1/20 0.33
▸ F2RL1 P55085 1/20 0.32
▸ MAPT P10636 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31104326 0.85 ALDH1A1 (0.36) ALDH1A1HTTRAB9ANPSR1NPC1
SCHEMBL31104092 0.83 ALDH1A1 (0.35) ALDH1A1HTTRAB9ANPSR1NPC1
SCHEMBL31103949 0.82 ALDH1A1 (0.33) ALDH1A1HTTRAB9ANPSR1NPC1
SCHEMBL31104413 0.80 HTT (0.36) ALDH1A1HTTRAB9ANPSR1NPC1
SCHEMBL21521058 0.79 HTT (0.49) ALDH1A1HTTRAB9ANPSR1NPC1
SCHEMBL25075159 0.73 ALDH1A1 (0.40) ALDH1A1HTTRAB9ANPSR1NPC1
SCHEMBL27077783 0.73 F2RL1 (0.32) NPC1F2RL1
SCHEMBL21519281 0.72 ALDH1A1 (0.40) ALDH1A1HTTRAB9ANPSR1NPC1
SCHEMBL26915819 0.71 F2RL1 (0.33) NPC1F2RL1
SCHEMBL31104140 0.71 NPC1 (0.35) ALDH1A1HTTRAB9ANPSR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 VIVIDION THERAPEUTICS, INC. 2025-02-20 — — US disclosed
WO-2024182693-A1 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER VIVIDION THERAPEUTICS, INC. (US) 2024-09-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 STAT3, JAK2, STAT1 ALDH1A1 2652/4885HTT 2654/4885RAB9A 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback